Basal insulin peglispro: Phase III data

Top-line data from the 26-week, open-label, international Phase III IMAGINE-6 trial in 641 insulin-naive Type II diabetics inadequately controlled on >=2 oral antihyperglycemic medications showed that once-daily subcutaneous basal insulin peglispro met the primary endpoint of non-inferiority to NPH insulin in reducing HbA1c from baseline to week 26. Eli Lilly also analyzed superiority for HbA1c lowering upon meeting the primary endpoint and basal insulin peglispro led to a significantly greater reduction on the endpoint vs. NPH insulin. ...